In-/Exclusion criteria

INFORM Registry

INFORM – INdividualized Therapy FOr Relapsed Malignancies in Childhood



Coordinating Investigator Registry: Prof. Dr. med. Olaf Witt

KiTZ Clinical Trial Unit

Kristian Pajtler / Ingrid Bauer

Tel. 06221-56-6913

Email: INFORM_info@DKFZ.de

Version and date: Version 5.0, dated 08.03.2019

German Clinical Trial Register ID: DRKS00007623

General Inclusion Criteria:

- Children, adolescents and young adults 0 to 40 years old with refractory/relapsed/progressive oncological disease following first, second or third line treatment protocols, including targeted treatment approaches considering entity-specific high risk criteria. High grade gliomas (incl. DIPG), specific soft tissue sarcomas, ETMR and rare tumor diseases included in the STEP-Registry, e.g. carcinoma, melanoma, rare gonadal tumors may be enrolled upon primary diagnosis.
- Patients can be included up until the age of 40 years, but they must have had their primary diagnosis below the age of 21 years.
- No established curative treatment options.
- Life expectancy > 3 months and sufficient general condition (Lansky ≥ 50 or Karnofsky ≥ 50).
- First-line treatment within one of the therapy optimization/registry trials of the GPOH or an equivalent protocol, except for specific primary soft tissue sarcomas, primary diagnosis high-grade gliomas (incl. DIPG), ETMR and rare tumor diseases included in the STEP-Registry.
- Residency in Germany or in one of the partner countries.
- Inclusion in INFORM Registry discussed with and agreed by respective GPOH Entity Study group (or with the respective national coordinator).
- Histopathological/molecular confirmation of clinically suspected diagnosis.
- Routine biopsy/puncture of the current refractory/relapsed/progressive oncological disease as part of standard of care treatment.
- Time between biopsy/puncture of the current oncological disease and receipt of all required samples and information in the INFORM sample processing laboratory at the CCU Neuropathology in Heidelberg < 8 weeks.
- For German patients with solid and brain tumors suitable fresh frozen tumor material of the current disease episode and non-malignant material will be sent to INFORM Registry for molecular analysis.

…

- For all international patients (and German patients with non-solid tumors) already extracted tumor DNA and tumor RNA from fresh frozen malignant material (tumor cell content at least 40%) of the current disease episode as well as DNA from non-malignant material will be sent to INFORM Registry for molecular analysis.
- Written informed consent of the patients and/or the legal guardians.

Entity specific in-/exclusion criteria:

ALL-HR

Inclusion Criteria:

- Refractory disease at first relapse (> 40% blasts in bone marrow)
- At least 2nd relapse post chemotherapy (>40% blasts in bone marrow)
- Bone marrow involvement

ALL post-SCT

Inclusion Criteria

- Bone marrow relapse of ALL (> 40% blasts in bone marrow)
- Post allogeneic hematopoietic stem cell transplantation

AML

Inclusion Criteria:

- Early 1st relapse AML/ refractory disease following re-induction,
  or at least 2nd relapse AML (>40% blasts in bone marrow or sorted blasts)

Exclusion Criteria:

- Acute promyelocytic leukemia
- Acute myeloid leukemia in patients with Down Syndrome

Soft tissue sarcoma

Inclusion Criteria:

- Combined or metastatic relapsed RMS,
  or first-line therapy: Progressive RMS, no option for local therapy,
  or primary diagnosis metastatic RMS in patients age > 10years or bone/bone marrow metastasis,
  or non-resectable desmoplastic small round cell tumor (primary diagnosis or refractory/relapsed/progressive DSRCT)
- Other sarcomas

Ependymoma, medulloblastoma and embryonal tumors

Inclusion Criteria:

- Medulloblastoma or ependymoma (WHO°II or III)
- Refractory or progressive disease following first-line therapy or first or multiple relapse
- Newly diagnosed ETMRs

Ewing sarcoma

Inclusion Criteria:

- Any relapsed and/or therapy refractory ewing sarcoma, including pPNET.
- Tumor at biopsy accessible site

High grade glioma (incl. diffuse intrinsic pontine glioma)

Inclusion Criteria:

- Primary diagnosis or relapsed/progressive high-grade malignant glioma (WHO grade 3 or 4 or analogous tumors incl. DIPG)

Neuroblastoma

Inclusion Criteria:

- High risk neuroblastoma patients; any neuroblastoma relapse after high risk therapy, **or** intermediate risk neuroblastoma patients: At least second relapse after HD chemotherapy and ASCT
- Relapsed tumor accessible to low risk surgery or, in case of bone marrow infiltration and only if tumor tissue not available, aspirate containing at least 40% neuroblast infiltration (% after cytospin, not in bone marrow smear)

NHL

Inclusion Criteria:

- Burkitt lymphoma, mature aggressive B-cell NHL not further classified or LBL with non-response, progression, or relapse

Osteosarcoma

Inclusion Criteria:

- Relapsed or first-line therapy refractory Osteosarcoma

Rhabdoid tumors

Inclusion Criteria:

- Relapse or first-line therapy refractory rhabdoid tumors

“Other” refractory or progressive/relapsed entities including rare tumor diseases

- Exceptional cases discussed with and agreed by INFORM Registry Trial Office
- In case of rare tumor diseases with the GPOH STEP registry
- In case of nephroblastoma, hepatoblastoma, retinoblastoma, malignant endocrine tumors, or germ cell tumors with the respective GPOH study group